SUBSCRIBE
SUBSCRIBE

Postmarket research

Drug Development
Chemotherapy and Tamoxifen Reduce Risk of Second Breast Cancer
December 26, 2007
 · 
1 min read
Drug Development
Ireland Cancer Center Researcher Finds Standard Treatment for Breast Cancer Not Followed
December 24, 2007
 · 
1 min read
Drug Development
Study Finds Low-Dose Pharma Drug Best after Transplant
December 20, 2007
 · 
1 min read
Drug Development
Duloxetine Improves Depression-Related Pain
December 19, 2007
 · 
1 min read
Drug Development
Lymphoma Drug Used To Treat Skin Disorders
December 18, 2007
 · 
1 min read
Drug Development
Study: Timing of Pills Might Matter
December 18, 2007
 · 
1 min read
Drug Development
Older Antibiotic Might Speed TB Treatment
December 18, 2007
 · 
1 min read
Drug Development
Drug Combination Shrinks Breast Cancer Metastases in Brain, Dana-Farber Cancer Institute Study
December 17, 2007
 · 
1 min read
Drug Development
Herceptin Helps Women With Multiple Chromosomes Containing HER2 Gene, Study Finds
December 17, 2007
 · 
1 min read
Drug Development
U.S. Panel Says Data Support Cold Medicines
December 17, 2007
 · 
1 min read
Load More
PRESS RELEASES
Drug Development
Roche’s Avastin Disappoints Against Ovarian Cancer
December 29, 2011
 · 
1 min read
Drug Development
Emergent BioSolutions Initiates Phase 2 Study of TRU-016 in Combination with Bendamustine in Patients with Relapsed Chronic Lymphocytic Leukemia
December 28, 2011
 · 
1 min read
Drug Development
Study Challenges Bristol-Myers Squibb Company on Bristol-Myers Squibb Company and Sanofi (France)'s Plavix
December 28, 2011
 · 
1 min read
Drug Development
Pfizer Inc. Reports Results From Three Phase 4 Studies Demonstrating EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII Impact on Drug Liking and Withdrawal Symptoms
December 22, 2011
 · 
7 min read
Drug Development
UCB, Inc. Announces Start of the EXXELERATE(TM) Clinical Study in Rheumatoid Arthritis
December 21, 2011
 · 
15 min read
Drug Development
Salix Pharmaceuticals, Ltd. and Progenics Pharmaceuticals, Inc. Announce Positive Highly Statistically Significant Results of Oral Methylnaltrexone for Phase 3 Trial in Chronic, Non-Cancer Pain Subjects with Opioid-Induced Constipation
December 20, 2011
 · 
9 min read
Drug Development
Genzyme Corporation Reports Failing Results for TENERE Study of Oral Teriflunomide in Relapsing Multiple Sclerosis
December 20, 2011
 · 
7 min read
Drug Development
Clinuvel Announces Positive Results From Pivotal European Phase III Study: Endpoints Demonstrate Clinically Relevant Treatment Effect of Afamelanotide
December 19, 2011
 · 
9 min read
Drug Development
EarlySense Release: Studies Show that EarlySense’s Contact-Free Patient Monitoring System Effectively Helps Hospital Patients Avoid Pressure Ulcers
December 19, 2011
 · 
1 min read
Drug Development
Lieff Cabraser Release: Fosamax and Boniva Drug Lawsuit Charges Permanent and Severe Injuries from Long-Term Bisphosphonate Use
December 16, 2011
 · 
1 min read
Drug Development
Pfizer Inc.'s Lyrica Helps in Phase III Restless Legs Syndrome Study
December 16, 2011
 · 
3 min read
Drug Development
Treatment of Patients With Malignant Mesothelioma Utilizing Photodynamic Therapy With Pinnacle Biologics’ Compound PHOTOFRIN(R) - Obtains FDA Orphan Drug Designation
December 15, 2011
 · 
4 min read
Drug Development
Human Genome Sciences, Inc. and GlaxoSmithKline Initiate Phase 3 Trial of Belimumab (BENLYSTA®) Administered Subcutaneously in Subjects with Systemic Lupus Erythematosus
December 15, 2011
 · 
1 min read
Drug Development
Celgene International Sárl Release: Final Phase II Data Evaluating REVLIMID® and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
December 14, 2011
 · 
1 min read
Drug Development
Celgene International Sárl Release: Phase III Study Evaluating REVLIMID® in Patients with High-Risk Smoldering Multiple Myeloma Presented at American Society of Hematology
December 14, 2011
 · 
1 min read
Drug Development
Celgene International Sárl Release: Premiere Cooperative Group in Adult Lymphoma Research (GELA) Chooses REVLIMID® for Study in Second Most Common Lymphoma Subtype
December 14, 2011
 · 
1 min read
Drug Development
Biovest International, Inc. Release: BiovaxID® Lymphoma Vaccine-Induced T-Cell Immune Responses Complement Rituximab Induction Chemotherapy and Significantly Correlate with Overall Survival in Mantle Cell Lymphoma
December 13, 2011
 · 
1 min read
Drug Development
Celgene International Sárl Release: REVLIMID® Evaluated in Combination with Rituximab as a Potential Treatment for Patients with Treatment-Naive Chronic Lymphocytic Leukemia
December 13, 2011
 · 
1 min read
Drug Development
Biovest International, Inc. Release: BiovaxID® Lymphoma Vaccine-Induced T-Cell Immune Responses Complement Rituximab Induction Chemotherapy and Significantly Correlate with Overall Survival in Mantle Cell Lymphoma
December 13, 2011
 · 
1 min read
Drug Development
Millennium: The Takeda Oncology Company Release: Overall Survival Benefit with VELCADE® Based Therapy in Previously Untreated Multiple Myeloma Patients Maintained After Five Year Follow-Up
December 13, 2011
 · 
1 min read
Load More